Valuation: Verastem, Inc.

Market Cap 53Cr 46Cr 43Cr 39Cr 74Cr 5.1TCr 76Cr 510.73Cr 200.88Cr 2.5TCr 199Cr 194.63Cr 8.6TCr P/E 2026 *
-3.81x
P/E 2027 * -5.38x
Enterprise Value 36Cr 32Cr 29Cr 27Cr 51Cr 3.51TCr 52Cr 351.69Cr 138.33Cr 1.72TCr 137.03Cr 134.02Cr 5.92TCr EV / Sales 2026 *
3.58x
EV / Sales 2027 * 1.8x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+4.51%
1 week+9.04%
Current month+57.85%
1 month+46.36%
3 months-8.36%
6 months-9.73%
Current year-21.89%
1 week 5.28
Extreme 5.28
6.07
1 month 3.43
Extreme 3.43
6.07
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
44.98
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06/26 Sell

Chief Executive Officer

-20,871 0.0339%
22/06/26 Sell

Chief Financial Officer

-4,089 0.0066%
21/05/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+4.51%+9.04%+16.86%-32.85% 53Cr
+0.24%-1.54%+52.85%+60.31% 5.38TCr
-7.17%-4.39%+42.72%+73.70% 5.21TCr
+0.80%-6.31%+5.62%+413.12% 2.35TCr
-0.09%-0.01%-16.85%-16.17% 2.31TCr
+3.95%+3.16%+37.50%-4.82% 1.94TCr
-1.14%+0.03%+31.67%-31.21% 1.76TCr
-5.16%-7.00%+168.44%+291.24% 1.52TCr
+4.85%+1.39%+35.33%+654.24% 1.48TCr
+0.43%-1.03%+25.75%+186.18% 1.41TCr
Average +0.16%-1.46%+39.99%+159.37% 2.34TCr
Weighted average by Cap. -1.19%-2.33%+40.80%+138.84%

Financials

2026 *2027 *
Net sales 10Cr 8.9Cr 8.22Cr 7.57Cr 14Cr 981.04Cr 15Cr 98Cr 39Cr 480.47Cr 38Cr 37Cr 1.65TCr 18Cr 16Cr 14Cr 13Cr 25Cr 1.72TCr 26Cr 171.9Cr 68Cr 841.17Cr 67Cr 66Cr 2.9TCr
Net income -17Cr -14Cr -13Cr -12Cr -23Cr -1.59TCr -24Cr -159.54Cr -63Cr -780.69Cr -62Cr -61Cr -2.69TCr -14Cr -12Cr -11Cr -11Cr -20Cr -1.37TCr -20Cr -136.93Cr -54Cr -670.04Cr -53Cr -52Cr -2.31TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.59TCr -24Cr -159.04Cr -63Cr -778.22Cr -62Cr -61Cr -2.68TCr -21Cr -18Cr -17Cr -16Cr -29Cr -2.02TCr -30Cr -202.03Cr -79Cr -988.57Cr -79Cr -77Cr -3.4TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
17/26/17 $6.030 +4.51% 35,62,397
16/26/16 $5.770 +0.70% 19,85,572
15/26/15 $5.730 +2.87% 20,83,595
14/26/14 $5.570 +3.72% 30,04,355
13/26/13 $5.370 -2.89% 24,17,232
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.030USD
Average target price
15.00USD
Spread / Average Target
+148.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock